The aetiology of hepatic dysfunction in patients with HIV infection is multifactorial. Re-activation of hepatitis C infection, drug toxicity, and opportunistic infections are all potential causes. Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection. It is associated with a significant incidence of hepatotoxicity, usually occurring in the initial month of therapy. We report the case of a 49-year-old man who developed NVP-induced prolonged hepatotoxicity 5 months after commencing antiretroviral therapy.
MontanerJSGReissPVellaS. A randomised, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV infected patients — The 1NCAS Trial. JAMA1998;279:930–7
2.
HavlirDCheesmanSHMcLaughlinM. High dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with HIV infection. J Infect Dis1995;171:537–4
3.
CarrAVellaSde JongMD. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS1996;10:635–41
4.
D'AquilaRTHughesMDJohnsonVA. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV infection. Ann Intern Med1996;124:1019–30
5.
SkowronGLeoungGDusekA. Stavudine, nelfinavir, and nevirapine: preliminary safety, activity and pharmacokinetic (PK) interactions (Abstract 350). 6th Conference on Retroviruses and Opportunistic Infections,Chicago, January 1999.
